Morgan Stanley analyst David Arcaro maintained an 'Overweight' rating on Sempra but lowered the price target from $104 to $100. This indicates a slightly less optimistic outlook on the stock's near-term valuation, despite the continued positive recommendation.
Morgan Stanley's analyst David Arcaro updated his coverage on Sempra, reiterating an 'Overweight' rating but reducing the price target from $104 to $100. This adjustment suggests a recalibration of the stock's valuation, likely due to updated financial models, market conditions, or company-specific factors that slightly temper previous expectations. While the 'Overweight' rating still implies a positive long-term outlook, the lowered price target could lead to short-term downward pressure or limit upside potential for Sempra shares as investors digest the revised valuation. For traders, this presents a moderate signal; the stock remains favored, but its immediate growth prospects might be viewed with slightly less enthusiasm.